

## Consolidated Profit & Loss Account For Continuing Operations

For the year ended 31 December	2001 \$m	2000 \$m
<b>Sales</b>	16,480	15,804
Cost of sales	(4,456)	(4,181)
Distribution costs	(122)	(210)
Research and development	(2,687)	(2,620)
Selling, general and administrative expenses	(5,427)	(5,032)
Other operating income	368	223
<b>Operating profit before exceptional items</b>	4,156	3,984
Exceptional items charged to operating profit	(202)	(322)
Operating profit	3,954	3,662
Share of joint ventures' and associates' operating profits	-	(149)
Profit on sale of fixed assets	10	-
Net interest and dividend income	113	138
Profit on ordinary activities before taxation	4,077	3,651
<b>Profit before taxation before exceptional items</b>	4,269	4,110
Exceptional items charged to profit before taxation	(192)	(459)
Taxation	(1,099)	(1,114)
<b>Profit on ordinary activities after taxation</b>	2,978	2,537
Attributable to minorities	(11)	(9)
<b>Net profit for the year</b>	2,967	2,528
Dividends to Shareholders	(1,225)	(1,236)
Earnings per Ordinary Share before exceptional items	\$1.77	\$1.64
Earnings per Ordinary Share	\$1.69	\$1.43
Diluted earnings per Ordinary Share	\$1.69	\$1.43
Weighted average number of Ordinary Shares in issue (millions)	1,758	1,768
Diluted average number of Ordinary Shares in issue (millions)	1,761	1,770

## Consolidated Profit & Loss Account For Continuing Operations

For the <b>quarter</b> ended 31 December	2001 \$m	2000 \$m
<b>Sales</b>	4,440	4,144
Cost of sales	(1,206)	(1,136)
Distribution costs	(33)	(42)
Research and development	(732)	(778)
Selling, general and administrative expenses	(1,443)	(1,317)
Other operating income	64	100
<b>Operating profit before exceptional items</b>	1,090	971
Exceptional items charged to operating profit	(76)	(100)
Operating profit	1,014	871
Share of joint ventures' and associates' operating profits	-	(156)
Profit on sale of fixed assets	-	-
Net interest and dividend income	12	82
Profit on ordinary activities before taxation	1,026	797
<b>Profit before taxation before exceptional items</b>	1,102	1,034
Exceptional items charged to profit before taxation	(76)	(237)
Taxation	(263)	(265)
<b>Profit on ordinary activities after taxation</b>	763	532
Attributable to minorities	(4)	1
<b>Net profit for the period</b>	759	533
Dividends to Shareholders	(820)	(830)
Earnings per Ordinary Share before exceptional items	\$0.47	\$0.42
Earnings per Ordinary Share	\$0.43	\$0.30
Diluted earnings per Ordinary Share	\$0.43	\$0.30
Weighted average number of Ordinary Shares in issue (millions)	1,750	1,766
Diluted average number of Ordinary Shares in issue (millions)	1,752	1,768

## Consolidated Balance Sheet

At 31 December	2001 \$m	2000 \$m
<b>Fixed assets</b>		
Tangible fixed assets	5,409	4,957
Goodwill and intangible assets	2,700	2,951
Fixed asset investments	23	11
	8,132	7,919
<b>Current assets</b>		
Stocks	2,402	2,105
Debtors	3,628	3,960
Cash and short-term investments	3,823	4,450
	9,853	10,515
<b>Total assets</b>	17,985	18,434
<b>Creditors due within one year</b>		
Short-term borrowings and current instalments of loans	(321)	(214)
Other creditors	(6,159)	(6,683)
	(6,480)	(6,897)
<b>Net current assets</b>	3,373	3,618
<b>Total assets less current liabilities</b>	11,505	11,537
<b>Creditors due after more than one year</b>		
Loans	(635)	(631)
Other creditors	(152)	(296)
<b>Provisions for liabilities and charges</b>	(896)	(1,068)
	(1,683)	(1,995)
<b>Net assets</b>	9,822	9,542
<b>Capital and reserves</b>		
Shareholders' funds – equity interests	9,786	9,521
Minority equity interests	36	21
<b>Shareholders' funds and minority interests</b>	9,822	9,542

## Statement of Total Recognised Gains and Losses

For the year ended 31 December	2001 \$m	2000 \$m
Net profit for the financial year	2,967	2,538
Exchange adjustments on net assets	(495)	(1,038)
Translation differences on foreign currency borrowings	18	154
Tax on translation differences on foreign currency borrowings	(6)	(42)
<b>Total recognised gains and losses for the financial year</b>	2,484	1,612

## Consolidated Cash Flow Statement

For the year ended 31 December	2001 \$m	Continuing Operations 2000 \$m	Total 2000 \$m
<b>Cash flow from operating activities</b>			
Operating profit before exceptional items	4,156	3,986	4,330
Depreciation and amortisation	860	870	988
Increase in working capital	(1,006)	(429)	(340)
Other non-cash movements	120	(84)	14
<b>Net cash inflow from operating activities before exceptional items</b>	4,130	4,343	4,992
Outflow related to exceptional items	(368)	(731)	(809)
<b>Net cash inflow from operating activities</b>	3,762	3,612	4,183
Returns on investments and servicing of finance	156	19	19
Tax paid	(792)	(497)	(648)
Capital expenditure and financial investment	(1,543)	(1,277)	(1,426)
Acquisitions and disposals	(44)	604	(169)
Net repayment of debt by Zeneca Agrochemicals	-	-	909
Equity dividends paid to Shareholders	(1,236)	(1,220)	(1,220)
<b>Net cash inflow before management of liquid resources and financing</b>	303	1,241	1,648
<b>Management of liquid resources</b>			
Movement in short-term investments and fixed deposits (net)	260	(608)	(608)
<b>Financing</b>	(959)	(400)	(400)
<b>(Decrease)/increase in cash in the year</b>	(396)	233	640

## Reconciliation of Cash Flow to Net Cash Funds

For the year ended 31 December	2001 \$m	Total 2000 \$m
Net funds at 1 January	3,605	2,169
Net cash flows before management of liquid resources and financing	303	1,648
Net cash flows from share issues and repurchases	(994)	(334)
Acquisitions and disposals	-	127
Other non cash changes	-	48
Exchange	(47)	(53)
<b>Net funds at 31 December</b>	2,867	3,605

# Notes to the Preliminary Announcement

## 1 BASIS OF PREPARATION AND ACCOUNTING POLICIES

The results for the year ended 31 December 2001 have been prepared in accordance with UK generally accepted accounting principles. The accounting policies applied are those set out in AstraZeneca PLC's 2000 Annual Report and Form 20-F. In 2001, the continued standardisation of accounting treatments across AstraZeneca has led certain subsidiaries to classify as cost of sales some elements of expense recorded as distribution costs in previous periods. The effect of this change in the year to 31 December 2001 is to reclassify approximately \$120m of costs. Previous periods have not been restated.

Continuing operations comprises the ongoing business of AstraZeneca and the Comparative Profit and Loss Account figures for 2000 exclude the results of the Agrochemicals business which was demerged on 13 November 2000. The full comparative Profit and Loss Account for 2000 is detailed in Note 2 below.

The results for the year ended 2001 presented in this preliminary announcement are extracted from, and are consistent with, those in the Group's audited financial statements for the year ended 31 December 2001 and those financial statements will be delivered to the Registrar of Companies following the Company's annual general meeting. The information in this preliminary announcement does not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2000 have been filed with the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

## 2 CONSOLIDATED PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2000

	Continuing Operations \$m	Discontinued Operations \$m	Total \$m
<b>Sales</b>	15,804	2,299	18,103
Cost of sales	(4,181)	(1,299)	(5,480)
Distribution costs	(210)	(76)	(286)
Research and development	(2,620)	(222)	(2,842)
Selling, general and administrative expenses	(5,032)	(399)	(5,431)
Other operating income	223	43	266
<b>Operating profit before exceptional items</b>	3,984	346	4,330
Exceptional items charged to operating profit	(322)	-	(322)
Operating profit	3,662	346	4,008
Share of joint ventures' and associates' operating losses	(149)	-	(149)
Profits less losses on sale, closure or demerger of operations	-	(150)	(150)
Net interest and dividend income	138	-	138
<b>Profit on ordinary activities before taxation</b>	3,651	196	3,847
Taxation	(1,114)	(185)	(1,299)
<b>Profit on ordinary activities after taxation</b>	2,537	11	2,548
Attributable to minorities	(9)	(1)	(10)
<b>Net profit for the year</b>	2,528	10	2,538
Dividends to Shareholders			(2,905)
<b>Loss retained for the year</b>			(367)
Earnings per Ordinary Share before exceptional items	\$1.64	\$0.12	\$1.76
Earnings per Ordinary Share	\$1.43	\$0.01	\$1.44
Diluted earnings per Ordinary Share	\$1.43	\$0.01	\$1.44

### 3 JOINT VENTURES AND ASSOCIATES

The Group's share of joint ventures' sales for the year ended 31 December 2001 amounted to \$183m and \$195m for the comparative period. Share of joint ventures' operating profits for the year ended 31 December 2001 amounted to nil, and for the comparative period \$(149)m. The 2000 results reflect operational losses of \$12m, together with an exceptional charge of \$88m to provide for impairment of the 50% interest in the seed company Advanta, and write off of related goodwill which had previously been taken to reserves.

### 4 ANALYSIS OF EXCEPTIONAL ITEMS CHARGED TO OPERATING PROFIT

The following are the components of the exceptional charges to operating profits from continuing operations which relate to the integration and synergy programme commenced after the AstraZeneca merger:

<u>For the year ended 31 December</u>	<u>2001 \$m</u>	<u>2000 \$m</u>
Cost of sales	34	11
Research and development	86	51
Selling, general and administrative expenses	82	260
<b>Total exceptional items charged to operating profit</b>	<b>202</b>	<b>322</b>

### 5 RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS

<u>For the year ended 31 December</u>	<u>2001 \$m</u>	<u>2000 \$m</u>
Shareholders' funds at beginning of year	9,521	10,302
Net profit for the period - from continuing operations	2,967	2,528
- from discontinued operations	-	10
Dividends to Shareholders	(1,225)	(2,905)
	1,742	(367)
Issue of AstraZeneca PLC Ordinary Shares	86	19
Repurchase of AstraZeneca PLC Ordinary Shares	(1,080)	(353)
Goodwill written back	-	862
Foreign currency adjustment	(483)	(926)
Minority interest buy out	-	(8)
Other movements	-	(8)
Net addition to Shareholders' funds	265	(781)
Shareholders' funds at end of year	9,786	9,521

## 6 NET CASH FUNDS

The table below provides an analysis of net cash funds and a reconciliation of net cash flow to movement in net cash funds.

	At 31 Dec 2000 \$m	Cash flow \$m	Other non-cash \$m	Exchange movement s \$m	At 31 Dec 2001 \$m
Loans due after 1 year	(631)	(11)	8	(1)	(635)
Current instalments of loans	(88)	(17)	(8)	6	(107)
<b>Total loans</b>	<b>(719)</b>	<b>(28)</b>	<b>-</b>	<b>5</b>	<b>(742)</b>
Short-term investments	3,429	(260)	-	(51)	3,118
Cash	1,021	(299)	-	(17)	705
Overdrafts	(113)	(97)	-	15	(195)
Short-term borrowings, excluding overdrafts	(13)	(7)	-	1	(19)
	4,324	(663)	-	(52)	3,609
<b>Net cash funds</b>	<b>3,605</b>	<b>(691)</b>	<b>-</b>	<b>(47)</b>	<b>2,867</b>
Issue of AstraZeneca PLC Ordinary Shares		(86)			
Repurchase of AstraZeneca PLC Ordinary Shares		1,080			
<b>Net cash inflow before management of liquid resources and financing</b>		<b>303</b>			

## 7 YEAR END PRODUCT SALES ANALYSIS

	World				US	
	2001 \$m	2000 \$m	Actual Growth %	Constant Currency Growth %	2001 \$m	Actual Growth %
<b>Gastrointestinal:</b>						
Losec	5,684	6,260	(9)	(7)	3,694	(13)
Nexium	580	17	n/m	n/m	456	n/m
Others	44	45	(2)	7	3	n/m
<b>Total Gastrointestinal</b>	<b>6,308</b>	<b>6,322</b>	<b>-</b>	<b>2</b>	<b>4,153</b>	<b>(2)</b>
<b>Cardiovascular:</b>						
Zestril	1,097	1,188	(8)	(6)	642	(7)
Seloken	722	577	25	28	440	47
Plendil	471	480	(2)	2	203	6
Atacand	414	293	41	46	154	29
Tenormin	404	471	(14)	(7)	53	(21)
Imdur	86	94	(9)	(3)	10	(29)
Others	343	374	(8)	(3)	62	(3)
<b>Total Cardiovascular</b>	<b>3,537</b>	<b>3,477</b>	<b>2</b>	<b>6</b>	<b>1,564</b>	<b>8</b>
<b>Respiratory:</b>						
Pulmicort	775	705	10	14	276	80
Rhinocort	269	221	22	25	181	38
Accolate	146	152	(4)	(2)	102	(16)
Oxis	127	116	9	15	-	-
Bricanyl	107	125	(14)	(8)	-	-
Symbicort	83	-	n/m	n/m	-	-
Others	49	53	(8)	1	-	-
<b>Total Respiratory</b>	<b>1,556</b>	<b>1,372</b>	<b>13</b>	<b>17</b>	<b>559</b>	<b>38</b>
<b>Oncology:</b>						
Zoladex	728	734	(1)	5	207	9
Nolvadex	630	576	9	12	474	18
Casodex	569	433	31	37	241	27
Arimidex	191	156	22	27	61	15
Others	28	30	(7)	3	-	-
<b>Total Oncology</b>	<b>2,146</b>	<b>1,929</b>	<b>11</b>	<b>16</b>	<b>983</b>	<b>18</b>
<b>CNS:</b>						
Seroquel	700	424	65	67	568	51
Zomig	277	237	17	20	151	6
Others	22	24	(8)	(8)	6	(45)
<b>Total CNS</b>	<b>999</b>	<b>685</b>	<b>46</b>	<b>48</b>	<b>725</b>	<b>37</b>

## 7 YEAR END PRODUCT SALES ANALYSIS (CONTINUED)

	World				US	
	2001 \$m	2000 \$m	Actual Growth %	Constant Currency Growth %	2001 \$m	Actual Growth %
Pain, Infection and Other Pharma:						
Diprivan	465	507	(8)	(4)	217	(4)
Merrem	227	170	34	40	54	135
Xylocaine	212	238	(11)	(5)	59	(6)
Marcaine	87	92	(5)	-	31	(3)
Naropin	62	53	17	23	14	-
Other Pharma Products	458	563	(19)	(9)	139	(14)
<b>Total Pain, Infection and Other Pharma</b>	<b>1,511</b>	<b>1,623</b>	<b>(7)</b>	<b>-</b>	<b>514</b>	<b>(1)</b>
Salick Health Care	194	176	10	10	194	10
Astra Tech	126	114	11	19	8	60
Marlow Foods	103	90	14	22	-	-
Other	-	16	n/m	n/m	-	-
<b>Total</b>	<b>16,480</b>	<b>15,804</b>	<b>4</b>	<b>8</b>	<b>8,700</b>	<b>7</b>

n/m not meaningful

## 8 FOURTH QUARTER PRODUCT SALES ANALYSIS

	World				US	
	4 <sup>th</sup> Quarter 2001 \$m	4 <sup>th</sup> Quarter 2000 \$m	Actual Growth %	Constant Currency Growth %	4 <sup>th</sup> Quarter 2001 \$m	Actual Growth %
Gastrointestinal:						
Losec	1,397	1,728	(19)	(19)	848	(30)
Nexium	285	13	n/m	n/m	238	n/m
Others	14	11	27	36	3	n/m
<b>Total Gastrointestinal</b>	<b>1,696</b>	<b>1,752</b>	<b>(3)</b>	<b>(3)</b>	<b>1,089</b>	<b>(10)</b>
Cardiovascular:						
Zestril	265	228	16	15	148	42
Seloken	168	172	(2)	(3)	90	(10)
Plendil	139	127	9	10	69	21
Atacand	125	97	29	27	49	7
Tenormin	104	108	(4)	(1)	10	100
Imdur	22	21	5	5	2	(33)
Others	93	89	4	2	23	77
<b>Total Cardiovascular</b>	<b>916</b>	<b>842</b>	<b>9</b>	<b>9</b>	<b>391</b>	<b>19</b>

**8 FOURTH QUARTER PRODUCT SALES ANALYSIS (CONTINUED)**

	World				US	
	4 <sup>th</sup> Quarter 2001 \$m	4 <sup>th</sup> Quarter 2000 \$m	Actual Growth %	Constant Currency Growth %	4 <sup>th</sup> Quarter 2001 \$m	Actual Growth %
Respiratory:						
Pulmicort	205	193	6	4	76	29
Rhinocort	75	56	34	34	54	50
Accolate	31	21	48	48	19	46
Oxis	33	32	3	-	-	-
Bricanyl	27	31	(13)	(13)	-	-
Symbicort	49	-	n/m	n/m	-	-
Others	13	15	(13)	(6)	-	-
<b>Total Respiratory</b>	<b>433</b>	<b>348</b>	<b>24</b>	<b>23</b>	<b>149</b>	<b>38</b>
Oncology:						
Zoladex	209	181	15	17	53	66
Nolvadex	184	171	8	9	139	12
Casodex	176	119	48	50	73	62
Arimidex	52	39	33	33	13	8
Others	6	8	(25)	(12)	-	-
<b>Total Oncology</b>	<b>627</b>	<b>518</b>	<b>21</b>	<b>23</b>	<b>278</b>	<b>31</b>
CNS:						
Seroquel	174	131	33	34	130	15
Zomig	68	59	15	15	33	3
Others	6	-	n/m	n/m	1	n/m
<b>Total CNS</b>	<b>248</b>	<b>190</b>	<b>31</b>	<b>32</b>	<b>164</b>	<b>13</b>
Pain, Infection and Other Pharma:						
Diprivan	136	114	19	20	69	57
Merrem	65	48	35	37	17	42
Xylocaine	57	63	(10)	(7)	19	6
Marcaine	26	25	4	4	12	20
Naropin	19	14	36	36	5	25
Other Pharma Products	105	134	(22)	(9)	29	(34)
<b>Total Pain, Infection and Other Pharma</b>	<b>408</b>	<b>398</b>	<b>3</b>	<b>8</b>	<b>151</b>	<b>14</b>
Salick Health Care	50	41	22	22	50	22
Astra Tech	36	29	24	24	3	50
Marlow Foods	26	22	18	22	-	-
Other	-	4	n/m	n/m	-	-
<b>Total</b>	<b>4,440</b>	<b>4,144</b>	<b>7</b>	<b>8</b>	<b>2,275</b>	<b>5</b>

n/m not meaningful

## 9 FULL YEAR TERRITORIAL SALES ANALYSIS

	2001 \$m	2000 \$m	% Growth	
			Actual	Constant Currency
USA	8,700	8,153	7	7
Japan	851	825	3	16
France	967	886	9	15
Germany	693	699	(1)	4
Italy	638	555	15	21
Sweden	263	318	(17)	(4)
UK	777	820	(5)	1
Rest of World	3,591	3,548	1	8
<b>Total</b>	<b>16,480</b>	<b>15,804</b>	<b>4</b>	<b>8</b>

## 10 FOURTH QUARTER TERRITORIAL SALES ANALYSIS

	4 <sup>th</sup> Quarter 2001 \$m	4 <sup>th</sup> Quarter 2000 \$m	% Growth	
			Actual	Constant Currency
USA	2,275	2,177	5	5
Japan	260	244	7	16
France	266	224	19	13
Germany	182	171	6	-
Italy	181	138	31	24
Sweden	64	76	(16)	(7)
UK	226	217	4	3
Rest of World	986	897	10	13
<b>Total</b>	<b>4,440</b>	<b>4,144</b>	<b>7</b>	<b>8</b>

## Convenience Translation of Key Financial Information

For the three months ended 31 December	2001 \$m	2000* \$m	2001 £m	2000* £m	2001 SEKm	2000* SEKm
<b>Total Sales</b>	4,440	4,265	3,062	2,941	46,806	44,962
<b>Operating profit before exceptional items (EI)</b>	1,090	965	752	665	11,491	10,173
<b>Profit before tax on continuing operations before EI</b>	1,102	1,034	760	713	11,617	10,900
<b>Net profit for the year</b>	759	331	523	228	8,001	3,489
<b>Earnings per Ordinary Share pre EI</b>	\$0.47	\$0.42	£0.32	£0.29	SEK4.95	SEK4.43

For the year ended 31 December	2001 \$m	2000* \$m	2001 £m	2000* £m	2001 SEKm	2000* SEKm
<b>Total Sales</b>	16,480	18,103	11,364	12,484	173,732	190,842
<b>Operating profit before exceptional items (EI)</b>	4,156	4,330	2,866	2,986	43,813	45,647
<b>Profit before tax on continuing operations before EI</b>	4,269	4,110	2,944	2,834	45,004	43,328
<b>Net profit for the year</b>	2,967	2,538	2,046	1,750	31,278	26,756
<b>Basic earnings per Ordinary Share</b>	\$1.69	\$1.44	£1.17	£0.99	SEK17.82	SEK15.18
<b>Earnings per Ordinary Share pre EI</b>	\$1.77	\$1.76	£1.22	£1.21	SEK18.66	SEK18.55
<b>Dividend per Ordinary Share</b>	\$0.70	\$0.70	49.3p	47.4p	SEK7.45	SEK6.59
<b>Net cash inflow from operating activities</b>	3,762	4,183	2,594	2,885	39,659	44,097
<b>(Decrease)/increase in cash</b>	(396)	640	(273)	441	(4,175)	6,747
<b>Shareholders' funds – equity interests 31 December</b>	9,786	9,521	6,748	6,566	103,164	100,370

\* includes discontinued operations except for profit before tax on continuing operations before EI.

Sterling (£) and Swedish Kronor equivalents are shown for convenience and have been calculated using the current period end rates of \$1=£0.689584 and \$1=SEK10.542000, respectively. Dividend per Ordinary Share is shown as the actual amount payable using the rates at the date of declaration of the dividend.

## Information for US Investors

### RECONCILIATION TO UNITED STATES ACCOUNTING PRINCIPLES

The Group profit and loss account and Group balance sheet set out on pages 9, 10, 11 and 13 are prepared in accordance with generally accepted accounting principles in the United Kingdom (UK GAAP) which differ in certain material respects from those generally accepted in the United States (US GAAP). The differences as they apply to AstraZeneca PLC are explained in the Group's 2000 Annual Report and Form 20-F. In the current year, AstraZeneca adopted SFAS No. 133 "Accounting for Derivative Instruments and Hedging Activities". The approximate effects on Group income and shareholders' equity of the GAAP differences are shown below.

Income attributable to Shareholders	2001 \$m	2000 \$m
Net income for the year under UK GAAP	2,967	2,538
Adjustments to conform to US GAAP		
Purchase accounting adjustments, (including goodwill and tangibles);		
- deemed acquisition of Astra		
- amortisation and other acquisition adjustments	(1,514)	(1,756)
- others	-	(20)
Capitalisation, less disposals and amortisation of interest	57	45
Deferred taxation		
- on fair value of Astra	249	284
- others	(259)	(146)
Pension expense	(33)	(50)
Post-retirement benefits/plan amendment	4	4
Software costs capitalised	(10)	98
Restructuring costs	(22)	(97)
Unrealised gains/(losses) on foreign exchange and others	(74)	(35)
<b>Net income before cumulative effect of change in accounting policy</b>	<b>1,365</b>	<b>865</b>
Cumulative effect of change in accounting policy, net of tax, on adoption of SFAS No. 133	32	-
Net income in accordance with US GAAP	1,397	865
Net income from continuing operations	1,397	907
Net income/(loss) from discontinued operations	-	(42)
Net income per Ordinary Share under US GAAP (basic)	\$0.79	\$0.49
Net income per Ordinary Share under US GAAP (diluted)	\$0.79	\$0.49

## RECONCILIATION TO UNITED STATES ACCOUNTING PRINCIPLES

Shareholders' equity	31 Dec 2001 \$m	31 Dec 2000 \$m
Shareholders' equity under UK GAAP	9,786	9,521
Adjustment to conform to US GAAP		
Purchase accounting adjustments, (including goodwill and tangibles);		
- deemed acquisition of Astra		
- goodwill	11,062	12,610
- tangible and intangible fixed assets	8,139	9,510
- others	31	31
Capitalisation, less disposals and amortisation of interest	192	135
Deferred taxation		
- on fair value of Astra	(2,313)	(2,702)
- others	(268)	(278)
Dividend	820	830
Pension expense	(162)	(129)
Post-retirement benefits/plan amendment	(28)	(32)
Software costs capitalised	110	120
Restructuring costs	-	22
Others	33	69
<b>Shareholders' equity in accordance with US GAAP</b>	<b>27,402</b>	<b>29,707</b>

# Shareholder Information

## ANNOUNCEMENTS AND MEETINGS

---

Announcement of First Quarter Results 2002	25 April 2002
Annual General Meeting	25 April 2002
Announcement of Half Year Results 2002	25 July 2002
Announcement of Third Quarter Results 2002	24 October 2002
Annual Business Review	Week commencing 4 November 2002

## DIVIDENDS

---

The record date for the first interim dividend paid on 5 October 2001 (in the UK, Sweden and the US) was 24 August 2001. Ordinary Shares traded ex-dividend on the London and Stockholm Stock Exchanges from 22 August 2001. ADRs traded ex-dividend on the New York Stock Exchange from the same date.

The record date for the second interim dividend for 2001 payable on 8 April 2002 (in the UK, Sweden and the US) will be 22 February 2002. Ordinary Shares will trade ex-dividend on the London and Stockholm Stock Exchanges from 20 February 2002. ADRs will trade ex-dividend on the New York Stock Exchange from the same date.

Future dividends will normally be paid as follows:

First interim	Announced end of July and paid in October.
Second interim	Announced in January and paid in April.

## TRADE MARKS

---

The following brand names used in this interim report are trade marks of the AstraZeneca group of companies:

**Accolate Arimidex Astra Tech Atacand Atacand HCT Atacand Plus Bricanyl Casodex Crestor Doprivan Faslodex Imdur Iressa Losec Marcaine Merrem Naropin Nexium Nolvadex Oxis Plendil Prilosec Pulmicort Pulmicort Respules Rhinocort Rhinocort Aqua Seloken Seroquel Symbicort Tenormin Toprol-XL Xylocaine Zestril Zoladex Zomig Zomig Rapimelt Zomig ZMT**

## ADDRESSES FOR CORRESPONDENCE

---

<b>Registrar and Transfer Office</b>	<b>Depository for ADRs</b>	<b>Registered Office</b>	<b>Swedish Securities Register Centre</b>
The AstraZeneca Registrar Lloyds TSB Registrars The Causeway Worthing West Sussex BN99 6DA Tel: (0870) 600 3956	Morgan Guaranty Trust Company of New York ADR Service Center PO Box 842006 Boston, MA 02284-2006 Tel: (781) 575 4328	15 Stanhope Gate London W1K 1LN Tel: (020) 7304 5000	VPC AB Box 7822 S-103 97 Stockholm Sweden Tel: (8) 402 9000

## CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

---

In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Preliminary Report contains forward-looking statements with respect to the financial condition, results of operations and businesses of AstraZeneca. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims and exposure to environmental liability.